{"pmid":32388480,"title":"Can beta-adrenergic blockers be used in the treatment of COVID-19?","text":["Can beta-adrenergic blockers be used in the treatment of COVID-19?","Med Hypotheses","Vasanthakumar, Natesan","32388480"],"journal":"Med Hypotheses","authors":["Vasanthakumar, Natesan"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388480","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109809","keywords":["ace2","ards","beta-adrenergic blockers","covid-19","sars-cov-2","septic shock"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892614754305,"score":9.490897,"similar":[{"pmid":32356926,"title":"Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.","text":["Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19.","In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease was named COVID-19 and the causative virus SARS-CoV-2. The SARS-CoV-2 virus enters the airway and binds, by means of the S protein on its surface to the membrane protein ACE2 in type 2 alveolar cells. The S protein-ACE2 complex is internalized by endocytosis leading to a partial decrease or total loss of the enzymatic function ACE2 in the alveolar cells and in turn increasing the tissue concentration of pro-inflammatory angiotensin II by decreasing its degradation and reducing the concentration of its physiological antagonist angiotensin 1-7. High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an inflammatory process with release of proinflammatory cytokines, establishing a self-powered cascade, leading eventually to ARDS. Recently, Gurwitz proposed the tentative use of agents such as losartan and telmisartan as alternative options for treating COVID-19 patients prior to development of ARDS. In this commentary article, the authors make the case for the election of telmisartan as such alternative on the basis of its pharmacokinetic and pharmacodynamic properties and present an open-label randomized phase II clinical trial for the evaluation of telmisartan in COVID-19 patients (NCT04355936).","Drug Dev Res","Rothlin, Rodolfo Pedro","Vetulli, Hector Miguel","Duarte, Mariano","Pelorosso, Facundo German","32356926"],"abstract":["In late 2019, a new coronavirus emerged in Wuhan Province, China, causing lung complications similar to those produced by the SARS coronavirus in the 2002-2003 epidemic. This new disease was named COVID-19 and the causative virus SARS-CoV-2. The SARS-CoV-2 virus enters the airway and binds, by means of the S protein on its surface to the membrane protein ACE2 in type 2 alveolar cells. The S protein-ACE2 complex is internalized by endocytosis leading to a partial decrease or total loss of the enzymatic function ACE2 in the alveolar cells and in turn increasing the tissue concentration of pro-inflammatory angiotensin II by decreasing its degradation and reducing the concentration of its physiological antagonist angiotensin 1-7. High levels of angiotensin II on the lung interstitium can promote apoptosis initiating an inflammatory process with release of proinflammatory cytokines, establishing a self-powered cascade, leading eventually to ARDS. Recently, Gurwitz proposed the tentative use of agents such as losartan and telmisartan as alternative options for treating COVID-19 patients prior to development of ARDS. In this commentary article, the authors make the case for the election of telmisartan as such alternative on the basis of its pharmacokinetic and pharmacodynamic properties and present an open-label randomized phase II clinical trial for the evaluation of telmisartan in COVID-19 patients (NCT04355936)."],"journal":"Drug Dev Res","authors":["Rothlin, Rodolfo Pedro","Vetulli, Hector Miguel","Duarte, Mariano","Pelorosso, Facundo German"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356926","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/ddr.21679","keywords":["ace2","ards","covid-19","sars-cov-2","angiotensin ii","clinical trial","telmisartan"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Losartan","Telmisartan"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495176933376,"score":86.01967},{"pmid":32340759,"pmcid":"PMC7129207","title":"Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus Disease 2019 (COVID-19).","text":["Inappropriate Antibiotic Consumption as a Possible Cause of Inflammatory Storm and Septic Shock in Patients Diagnosed with Coronavirus Disease 2019 (COVID-19).","The novel coronavirus (SARS-CoV-2) infection which has been known as Coronavirus diseases 2019 (COVID-19) has become an endemic emergent situation by the World Health Organization. So far, no successful specific treatment has been found for this disease. As has been reported, most of non-survivor patients with COVID-19 (70%) had septic shock which was significantly higher than survived ones. Although the exact pathophysiology of septic shock in these patients is still unclear, it seems to be possible that part of it would be due to the administration of empiric antibiotics with inflammatory properties especially in the absence of bacterial infection. Herein, we have reviewed possible molecular pathways of septic shock in the patients who have received antibiotics with inflammatory properties which mainly is release of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF- alpha) through different routes. Altogether, we highly recommend clinicians to look after those antibiotics with anti-inflammatory activity for both empiric antibiotic therapy and reducing the inflammation to prevent septic shock in patients with diagnosed COVID-19.","Arch Med Res","Hantoushzadeh, Sedigheh","Norooznezhad, Amir Hossein","32340759"],"abstract":["The novel coronavirus (SARS-CoV-2) infection which has been known as Coronavirus diseases 2019 (COVID-19) has become an endemic emergent situation by the World Health Organization. So far, no successful specific treatment has been found for this disease. As has been reported, most of non-survivor patients with COVID-19 (70%) had septic shock which was significantly higher than survived ones. Although the exact pathophysiology of septic shock in these patients is still unclear, it seems to be possible that part of it would be due to the administration of empiric antibiotics with inflammatory properties especially in the absence of bacterial infection. Herein, we have reviewed possible molecular pathways of septic shock in the patients who have received antibiotics with inflammatory properties which mainly is release of interleukin 1beta (IL-1beta), IL-6, and tumor necrosis factor alpha (TNF- alpha) through different routes. Altogether, we highly recommend clinicians to look after those antibiotics with anti-inflammatory activity for both empiric antibiotic therapy and reducing the inflammation to prevent septic shock in patients with diagnosed COVID-19."],"journal":"Arch Med Res","authors":["Hantoushzadeh, Sedigheh","Norooznezhad, Amir Hossein"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32340759","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.arcmed.2020.03.015","keywords":["antibiotics","coronavirus diseases 2019","inflammation","sars-cov-2","septic shock"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1666138495862702080,"score":68.63453},{"pmid":32304747,"pmcid":"PMC7158830","title":"Angiotensin receptor blockers and COVID-19.","text":["Angiotensin receptor blockers and COVID-19.","Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients.","Pharmacol Res","Saavedra, Juan M","32304747"],"abstract":["Angiotensin Receptor Blockers (ARBs) exhibit major pleiotropic protecting effects beyond their antihypertensive properties, including reduction of inflammation. ARBs directly protect the lung from the severe acute respiratory syndrome as a result of viral infections, including those from coronavirus. The protective effect of ACE2 is enhanced by ARB administration. For these reasons ARB therapy must be continued for patients affected by hypertension, diabetes and renal disease, comorbidities of the current COVID-19 pandemic. Controlled clinical studies should be conducted to determine whether ARBs may be included as additional therapy for COVID-19 patients."],"journal":"Pharmacol Res","authors":["Saavedra, Juan M"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304747","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.phrs.2020.104832","keywords":["ace2","angiotensin receptor blockers","covid-19","coronavirus","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491087486979,"score":62.413517},{"pmid":32352407,"title":"Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","text":["Preventing cytokine storm syndrome in COVID-19 using alpha-1 adrenergic receptor antagonists.","Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases.","J Clin Invest","Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan","32352407"],"abstract":["Medications that target catecholamine-associated inflammation may prevent cytokine storm syndrome associated with COVID-19 and other diseases."],"journal":"J Clin Invest","authors":["Konig, Maximilian F","Powell, Michael A","Staedtke, Verena","Bai, Ren-Yuan","Thomas, David L","Fischer, Nicole M","Huq, Sakibul","Khalafallah, Adham M","Koenecke, Allison","Xiong, Ruoxuan","Mensh, Brett","Papadopoulos, Nickolas","Kinzler, Kenneth W","Vogelstein, Bert","Vogelstein, Joshua T","Athey, Susan","Zhou, Shibin","Bettegowda, Chetan"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32352407","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1172/JCI139642","e_drugs":["Catecholamines"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495698075648,"score":57.196465},{"pmid":32447232,"title":"COVID-19: beta-thalassemia subjects immunised?","text":["COVID-19: beta-thalassemia subjects immunised?","The novel coronavirus pneumonia (COVID-19) is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a novel virus of the coronavirus family, SARSCoV-2. A recent PRE-print study has showed a heme attack on the 1-beta chain of hemoglobin by COVID19. Beta-thalassemia results of a default in the hemoglobin beta-chain synthesis. 1,5% global population are heterozygotes for this disease. In this study, by a multiple linear regression, we have analyzed the evolution of COVID-19 infection in three Italian regions (Puglia, Sardinia, Sicilia) with different beta-thalassemic prevalences, in order to search a link. The results have showed that betathalassemic heterozygote population prevalence is correlated to immunity against COVID-19, by a regression. This paper is only for academic discussion, the hypotheses and conclusions needs to be confirmed by further research.","Med Hypotheses","Lansiaux, Edouard","Pebay, Philippe Pierre","Picard, Jean-Laurent","Son-Forget, Joachim","32447232"],"abstract":["The novel coronavirus pneumonia (COVID-19) is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a novel virus of the coronavirus family, SARSCoV-2. A recent PRE-print study has showed a heme attack on the 1-beta chain of hemoglobin by COVID19. Beta-thalassemia results of a default in the hemoglobin beta-chain synthesis. 1,5% global population are heterozygotes for this disease. In this study, by a multiple linear regression, we have analyzed the evolution of COVID-19 infection in three Italian regions (Puglia, Sardinia, Sicilia) with different beta-thalassemic prevalences, in order to search a link. The results have showed that betathalassemic heterozygote population prevalence is correlated to immunity against COVID-19, by a regression. This paper is only for academic discussion, the hypotheses and conclusions needs to be confirmed by further research."],"journal":"Med Hypotheses","authors":["Lansiaux, Edouard","Pebay, Philippe Pierre","Picard, Jean-Laurent","Son-Forget, Joachim"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447232","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.mehy.2020.109827","keywords":["beta thalassemia","correlation","favipiravir","heme","immunization","italy","novel coronavirus","regression","respiratory distress","sardinia","statistics"],"locations":["Italian","Sardinia","Sicilia"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667698385854922754,"score":52.38822}]}